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Summary
Background:  Dengue  hemorrhagic  fever  (DHF)  is  considered  to  be  associated  with
secondary  dengue  infection.  This  study  was  conducted  to  note  frequency  of  pri-
mary  and  secondary  dengue  infection  in  DHF  patients.  Additionally  these  patients
were  compared  in  terms  of  age,  gender,  laboratory  parameter,  diseases  severity  and
outcome.
Materials  and  methods:  In  this  cross  sectional  observational  study  DHF  patients
fulﬁlling  DHF  criteria  of  Dengue  Expert  Advisory  Group  (DEAG)  were  included  and
divided  into  groups  based  on  dengue  speciﬁc  IgG  positivity  and  ratio  of  IgM  to  IgG.
Group  I,  patients  with  secondary  dengue  infection  were  IgG  positive  or  their  ratio  of
IgM  to  IgG  was  <1.2.  Group  II,  primary  dengue  infection  patients  were  IgG  negative
or  their  ratio  of  IgM  to  IgG  was  >1.2.  The  two  Groups  were  compared  for  statistically
signiﬁcant  association  in  terms  of  age,  gender,  laboratory  parameter  (at  admission
hematocrit  [HCT],  platelet,  white  blood  cell  [WBC]  counts,  alanine  aminotransferase
[ALT]  value),  severity  (DHF  or  dengue  shock  syndrome),  and  outcome  (recovered  or
expired).
Results:  Two  hundred  thirty-four  DHF  patients  were  included.  66.2%  was  male  and
33.8%  female.  Mean  patient  age  was  28.8  ±  12.4  years.  Based  on  dengue  markers
results,  61.5%  patients  were  categorized  to  Group  I,  and  38.5%  to  Group  II.  Sta-
tistically  signiﬁcant  association  between  the  two  Groups  was  noted  in  terms  of  at
admission  platelet  count,  and  ALT  value,  P  value  <0.05.
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Dengue  infection:  The  diagnosis  of  dengue  infection
was based  on  the  DEAG  criteria  [13].
DHF: DHF  is characterized  by  plasma  leakageConclusion:  Primary  den
DHF  caused  by  secondar
and  higher  ALT  value.
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Introduction
Dengue  is  arthropod-borne  viral  illness  caused  by
infection with  one  of  the  4  serotypes  of  dengue
virus. Dengue  viruses  are  RNA  viruses  that  belong  to
the Flavivirus  genus.  Dengue  is  an  important  global
health care  issue.  At  least  3.6  billion  people  living
in more  than  125  tropical  and  subtropical  countries
are at  risk  of  developing  dengue  infection  [1].  Inter-
nationally,  up  to  22,000  deaths  are  attributed  to
dengue per  year  [2].
Dengue  infection  can  result  in  dengue  fever
(DF) and  dengue  hemorrhagic  fever  (DHF).  The
latter  is  further  divided  into  four  grades  depend-
ing upon  severity  [3,4].  Infection  with  one  of the
dengue  viruses  confers  lifelong  immunity  to  that
serotype.  If  a  person  is  infected  by  another  serotype
of dengue  virus  (secondary  infection),  problematic
versions of  dengue,  such  as  dengue  hemorrhagic
fever, may  develop  due  to  immune  enhancement
[4—6].  DHF  can  be  associated  with  poor  outcomes
depending on  the  facilities  available  for  patient
management [3,4].
The detections  of  the  NS1  antigen  and  dengue-
related IgM  and  IgG  antibodies  are  commonly  used
in dengue  diagnoses  [4,7].  NS1  is  virus-speciﬁc  non-
structural protein  that  can  be  detected  for  up  to
9 days  after  dengue  infection  [4].  IgM  antibodies
become detectable  in  most  patients  at  days  3—5  of
fever onset.  Tests  for  NS1  and  IgM  antibodies  have
high sensitivities  (∼90%)  and  speciﬁcities  (98%)  in
the diagnosis  of  dengue  at  ≥5  days  from  fever
onset. IgG  dengue-speciﬁc  antibodies  are  used  to
diagnose  prior  dengue  infections  [4].  Various  char-
acteristics  of  patients  with  dengue  infections  have
been the  focus  of  extensive  research.  However,
there is a  paucity  of  studies  that  have  focused  on
DHF patients  and  have  emphasized  primary  and  sec-
ondary infections.
The ﬁrst  outbreak  of  dengue  in  Pakistan  occurred
in 1994—1995.  Since  that  time,  dengue  has  increas-
ingly been  recognized  as  an  important  health
care issue  [8—10]. A  dengue  epidemic  occurred
in Rawalpindi,  Pakistan  from  July  to  December  of
2013 [11,12].  In this  epidemic,  1175  patients  suf-
fering from  dengue  infections  were  diagnosed  at
public sector  hospitals.  Of  the  811  patients  who
were managed  at  Holy  Family  Hospital,  Rawalpindi,
r
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o
l55  had  DHF.  This  study  sought  to  note  the  fre-
uencies of  primary  and  secondary  infections  in
HF patients.  Additionally,  age,  gender,  severity  of
HF, hematological  parameters  at  admission  (i.e.,
ematocrit  [HCT]  and  platelet  and  white  blood
ell [WBC]  counts),  alanine  aminotransferase  (ALT)
evel, duration  of  hospital  stay,  and  outcome  were
ompared  between  patients  with  primary  and  sec-
ndary dengue  infections.
aterials and methods
tudy and participants
his  cross  sectional,  observational  study  was  con-
ucted at the  Medical  Unit  of  the  Holy  Family
ospital, Rawalpindi  from  the  1st  of  July  2013
o the  31st  of  December,  2013.  All  patients  with
engue  infection  who  fulﬁlled  the  DHF  diagnos-
ic criteria  and  were  managed  at  this  hospital
ere evaluated.  Patients  with  illnesses  associated
ith hematological  abnormalities,  ascites  and/or
leural effusion  were  excluded.  These  exclusion
riteria included  chronic  liver  disease,  autoimmune
isorders, hematological  disorders,  renal  failure,
tc. Patients  with  unknown  dengue  IgG  statuses
ere also  excluded  from  the  study.  The  patients
ere managed  in  a standard  manner  as  per  the
engue Expert  Advisory  Group  (DEAG)  protocol  for
HF/dengue  shock  syndrome  (DSS)  [13].
thical considerations
his  study  was  approved  by  the  Departmental  Eth-
cal Committee,  and  the  patients  were  included
fter they  or  their  surrogates  provided  informed
onsent.
engue diagnostic criteriaevealed by  hemoconcentration  (an  increase  in
ematocrit  ≥20%  above  the  age-adjusted  average
r a decrease  in  hematocrit  ≥20%  of  the  base-
ine following  ﬂuid  replacement  therapy),  pleural
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eengue  hemorrhagic  fever:  Comparison  of  patients
ffusion,  ascites,  or  hypoproteinemia  plus  one  of
he following:  febrile  illness  of  2—7  days  duration,
emorrhagic manifestations  or  a  positive  tourni-
uet test,  and  thrombocytopenia  ≤100,000/mm3
13,14].
DSS: DSS  is  severe  version  of  DHF.  DSS  exhibited
ll of  the  features  of  DHF  and  circulatory  failure
videnced by  a  rapid,  weak  pulse,  a  low  pulse
ressure (20  mmHg)  or  age-speciﬁc  hypotension  and
old, clammy  skin,  and  restlessness  [13—15].
Primary and  secondary  dengue  infections:  Each
atient’s  serological  status  pertaining  to  dengue
nfection  was  determined  based  on  NS1  and  dengue-
peciﬁc IgM  and  IgG  positive  or  negative  results
nd titers.  These  tests  were  performed  using  the
D Dengue  Capture  ELISA  Kit  for  dengue  NS1,  IgM
nd IgG.  This  kit  has  sensitivities  and  speciﬁcities,
espectively, of  92.7%  and  98.4%  for  NS1,  96.4%  and
8.9% for  IgM,  and  98.8%  and  99.2%  for  IgG.  Based
n IgG  positivity  and  the  ratio  of  IgM  to  IgG,  the
atients were  categorized  into  secondary  (Group
) and  primary  (Group  II)  dengue  infection  groups.
roup  I patients  were  NS1-  and/or  IgM-positive  [16].
dditionally, these  patients  were  IgG-positive  or
ad ratios  of  IgM  to  IgG  <1.2  [7,16—18].  The  Group
I patients  were  NS1-  and/or  IgM-positive  and  were
gG-negative  or  exhibited  ratios  of  IgM  to  IgG  >1.2
hen they  were  IgG-positive  [4,7,17,18].
ata and statistical analysis
roup,  age,  gender  (male,  female),  duration  of
tay, outcome  (discharged  or  expired),  and  HCT,
BC, platelet  count,  and  ALT  value  at  admission  for
ach patient  were  noted  on  a  speciﬁcally  designed
ro forma.  For  each  group,  the  frequencies  and
ercentages  were  calculated  for  the  qualitative
ariables, and  the  means  ±  the  SDs  were  calcu-
ated for  the  quantitative  variables.  Statistically
igniﬁcant associations  between  the  two  Groups
ere identiﬁed  with  t-tests,  Chi-squared  tests,  or
isher’s exact  tests,  as  appropriate.  Sub-analyses
f the  secondary  and  primary  DHF  patients  in
erms of  severity  (i.e.,  DHF  or  DSS)  were  also
erformed.
esults
wo  hundred  ﬁfty-ﬁve  (255)  patients  with  DHF  were
dentiﬁed.  The  dengue  IgG  statuses  of  some  of the
atients were  not  known,  and  these  patients  were
xcluded.  Ultimately,  234  patients  were  included  in
he study,  Fig.  1  provided  details  about  the  included
atients.  One  hundred  ﬁfty-ﬁve  (66.2%)  patients
c
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ere  male,  and  79  (33.8%)  were  female.  The  mean
atient  age  was  28.8  ± 12.4  years.  Two  hundred
wenty-three (95.3%)  patients  were  diagnosed  with
HF, and  11  (4.7%)  were  diagnosed  with  DSS.  Two
undred  twelve  (90.6%)  patients  recovered  and
ere discharged,  8  (3.4%)  expired,  9  (3.8%)  were
ischarged  on  request,  and  5  (2.1%)  left  against
edical advice.
Based on  the  dengue  marker  results,  61.5%  of
he patients  were  categorized  as  Group  I,  and
8.4% were  categorized  as  Group  II  (Fig.  1).  The
ges, genders,  severity-based  dengue  diagnoses
i.e., DHF  or  DSS),  durations  of  hospital  stays,
utcome-based analysis  and  hematocrit,  platelet,
nd WBC  counts  at  admission  for  the  two  groups  are
iven in  Table  1. Statistically  signiﬁcant  associations
ere noted  between  the  Group  I and  II  patients  in
erms of  platelet  count  and  ALT  value  at  admis-
ion. Regarding  disease  severity,  95.1%  of  the  Group
 patients  had  DHF,  and  4.9%  of  these  patients  had
SS. Similarly,  95.5%  of  the  Group  II  patients  had
HF, and  4.5%  of  these  patients  had  DSS.  Detailed
omparisons of  the  disease  severities  of  the  Group
 and  II patients  are  provided  in  Tables  2  and  3,
espectively.
iscussion
n  exaggerated  immune  response  or  an  immune
nhancement is  thought  to  be  an  important  patho-
hysiological  basis  of  the  development  DHF  and
SS, which  are  severe  versions  of  dengue  infection
5,6]. The  antibodies  that  develop  as  a result  of
engue  infection  confer  immunity  against  that  par-
icular dengue  virus  type  but  are  non-neutralizing
or infections  caused  by  other  dengue  virus
erotypes. Such  infections  by  alternate  dengue
irus serotypes  combined  with  cross-reactive  T
ells are  believed  to  cause  most  of  the  manifes-
ations of  DHF/DSS  [5,6]. Secondary  infections  are
hus more  frequently  associated  with  DHF/DSS.  The
ajority of  our  patients  had  secondary  dengue
nfections.
DHF rarely  results  from  primary  dengue  infec-
ion [19,20]. However,  our  ﬁndings  in this  regard
re unusual  in  that  a greater  proportion  of  the  DHF
atients  (36.3%)  had  primary  dengue  infections.
o-infection with  more  than  one  viral  serotype
nd unknown  viral  and  host  factors  seem  to  be
esponsible  for  this  observation  [21,5,22—25]. How-
ver, an  appropriate  explanation  for  our  results
annot be  provided  due  to  the  limitations  of
his study;  i.e.,  the  sole  reliance  on  IgG  posi-
ivity and/or  the  IgM:IgG  ratio  as  a marker  of
econdary dengue  infection,  the  timing  of  the
492  M. Khurram  et  al.
Table  1  Comparison  of  patients  with  primary  (Group  II)  and  secondary  (Group  I)  dengue  infection.
Group  I  (144/234)  95%CIa Group  II  (90/234)  95%CIa P  value
Age  29  ±  13  ±2.14  28.5  ±  11.4  ±2.36  0.76
Gender
Male  96  (66%) ±7.74 59  (65.55%) ±9.82  0.43
Female  48  (33%) ±7.68 31  (34.44%) ±9.82
Diagnosis
DHF  137  (95.13%)  ±3.52  86  (95.55%)  ±4.28  0.45
DSS  7  (4.86%)  ±3.51  4  (4.44%)  ±4.26
Hematocritb (%)  40.4  ±  5.4  ±1.83  41.1  ±  4.6  ±2.77  0.60
Plateletsb (/mm3)  37,286.9  ±  24,026.4  ±3937.94  54,813.3  ±  34,471.8  ±7121.82  0.00004
WBCb (/mm3)  4.8  ±  2.9  ±0.48  4.4  ±  2.4  ±0.51  0.25
ALTb (Units/L)  160.1  ±  177.1  ±35.26  99.7  ±  85.6  ±22.24  0.0005
Duration  of  stay  (days)  4.3  ±  1.6  ±0.27  4.4  ±  1.8  ±0.4  0.66
Outcomec
Expired  5  (3.7%)  ±3.08  3  (3.52%)  ±3.81  0.48
Recovered  130  (96.29%)  ±3.09  82  (96.4%)  ±3.85
a Conﬁdence interval.
b At admission.
c Patients who were discharged on request or left against medical advice were not included.
Table  2  Secondary  dengue  infection  patients:  DHF/DSS  wise  comparison.
DHF  (137/144) 95%CIa DSS  (7/144) 95%CIa P  value
Age  28.9  ±  13.1  ±2.21  31.3  ±  10.5  ±8.45  0.757
Gender
Male  89  (64.9%)  ±7.8  7  (100%)  ±0000  0.05
Female  48  (35.1%)  ±7.8  0  (0%)  ±0000
Hematocritb (%)  40.4  ±  5.4  ±1.93  43.4  ±  5.7  ±5.64  0.21
Plateletsb (/mm3)  36,581  ±  22,504  ±3782.14  51,000  ±  45,125  ±33,428.94  0.43
WBCb (/mm3)  4.7  ±  2.8  ±0.48  5.8  ±  3.9  ±2.88  0.48
ALTb (Units/L)  152.4  ±  169  ±34.93  259.1  ±  256.7  ±191.7  0.07
Duration  of  stay  (days)  4.3  ±  1.2  ±0.21  5.1  ±  5.1  ±3.81  0.0000001
Outcomec
Expired  0  (0%)  ±0000  5  (71.4%)  ±33.48  0.0000001
Recovered  128  (100%)  ±0000  2  (28.6%)  ±33.48
a Conﬁdence interval.
b At admission.
c Patients who were discharged on request or left against medical advice were not included.
Table  3  Primary  dengue  infection  patients:  DHF/DSS  wise  comparison.
DHF  (86/90)  95%CIa DSS  (4/90)  95%CIa P  value
Age  28.2  ±  11.1  ±2.36  35.5  ±  16.5  ±16.21  0.18
Gender
Male  56  (62.2%)  ±10.02  3  (75%)  ±42.43  0.9
Female  30  (37.8%)  ±10.02  1  (25%)  ±42.43
Hematocritb (%)  41.1  ±  4.6  ±2.19  40.9  ±  18.4  ±25.58  0.98
Plateletsb (/mm3)  54,409  ±  33,526  ±7085.77  63,500  ±  57,448  ±56,298.4  0.7
WBCb (/mm3)  4.2  ±  2.2  ±0.5  8.3  ±  4.1  ±4.03  0.03
ALTb (Units/L)  101.3  ±  87.1  ±23.26  71.6  ±  52.3  ±59.19  0.43
Duration  of  stay  (days)  4.3  ±  1.5  ±0.33  6.5  ±  5.8  ±5.68  0.000000134
Outcomec
Expired  0  (0%)  ±0000  3  (75%)  ±42.43  0.00002
Recovered 81  (100%)  ±0000  1  (25%)  ±42.43
a Conﬁdence interval.
b At admission.
c Patients who were discharged on request or left against medical advice were not included.
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ampling,  and  the  acquisition  of  single  samples  for
erodiagnosis.
We did  not  observe  a  difference  in  the  sever-
ty of  DHF  between  the  patients  with  primary  and
econdary  infections.  A  sub-group  analysis  in  a
tudy conducted  in  Thailand  revealed  that  18.8%
f patients  with  primary  infections  and  42%  of  the
atients  with  secondary  infection  developed  severe
orms of  dengue  [26].  Another  study  reported  that
7.7% of  primary  and  94.4%  of  secondary  dengue
nfection patients  had  DHF.  In  the  same  study,  17.3%
f patients  with  primary  infection  were  found  to
ave DSS,  and  50.4%  of  the  patients  with  secondary
nfections had  DSS  [25]. Another  study  reported
hat DSS  was  observed  only  in  patients  with  sec-
ndary  dengue  infections  [15].
The mortality  of  DHF  varies  by  location  depend-
ng on  expertise  of  the  management  teams  and
he severity  of  illness  at  the  time  of  admission
27].  DHF/DSS-related  mortality  is  2—44%  [27]. In Malaysian  study  that  reviewing  the  mortality  of
HF, 100%  of  DHF  mortalities  were  attributed  to
econdary  dengue  infections  [17]. A  Pakistani  study
eported  that  75%  of  DSS-related  mortalities  were
h
m
cing  patients  and  Groups.
ue  to  secondary  dengue  infections  [16]. No  signiﬁ-
ant difference  between  the  mortalities  of  the  DHF
atients  with  primary  and  secondary  infections  was
bserved in  our  study.
We  did  not  observe  signiﬁcant  differences
etween  the  primary  and  secondary  DHF  patients
n terms  of  age,  gender,  disease  severity,  dura-
ion of  stay,  outcome,  or  hematocrit  or  WBC  counts
t admission.  However,  the  patients  with  sec-
ndary DHF  exhibited  signiﬁcantly  reduced  platelet
ounts  and  elevated  higher  ALT  values  at  admis-
ion, and  these  results  are  indicative  of  severe
isease [17]. Interestingly,  a sub-analysis  of  the  ill-
ess severities  (i.e.,  DHF  or  DSS)  of  our  primary
nd secondary  infection  patients  revealed  signiﬁ-
ant differences  in  the  durations  of  hospital  stays
nd outcomes.  Additionally,  the  initial  platelet
ounts of  the  primary  dengue  infection  patients  dif-
ered signiﬁcantly  based  on  the  diagnosis  of  DHF
r DSS.
The  goal  of  dengue  management  is  to  stabilize
emodynamic  the  statuses  of  DHF/DSS  patients  to
aintain perfusion  of  the  vital  organs  during  the
ritical phase.  Predicting  the  development  of  DHF
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[21] Anderson KB, Gibbons RV, Cummings DA, Nisalak A, Green
S, Libraty DH, et al. A shorter time interval between ﬁrst494  
or  DSS  in  a  particular  patient  at  the  onset  of dengue
infection is  difﬁcult.  Patients  with  dengue  infection
who exhibit  warning  signs  and/or  clinical  features
that are  suggestive  of  the  onset  of  DHF  are  hospital-
ized. This  situation  is  costly  for  socioeconomically
disadvantaged  facilities,  such  as  our  own,  in  which
other health  care  resources  must  be  diverted  for
the management  of  dengue  patients.  This  diversion
of resources  can  potentially  increase  the  suffer-
ing of  patients  with  other  illnesses.  It  is  possible
that the  recognition  of  secondary  dengue  infec-
tion and  the  focused  management  of  these  patients
might  improve  outcomes  [4,16].  The  important
implication of  ﬁndings  is  that  prompt  and  efﬁcient
management is  the  key  to  successful  treatment
of dengue-infected  patients.  The  erroneous  belief
that primary  dengue  infection  rarely  causes  DHF
may prove  to  be  problematic.
Conclusion
DHF  is  frequently  caused  by  primary  dengue  infec-
tion. The  DHF  patients  with  secondary  dengue
infection exhibited  lower  platelet  counts  and  ALT
values at  admission.  The  DHF  patients  with  pri-
mary and  secondary  infections  did  not  signiﬁcantly
differ in  terms  of  age,  gender,  disease  severity,
duration of  stay,  outcome  or  HCT  or  WBC  count  at
admission.
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